Single nucleotide polymorphisms in the progesterone receptor gene and association with uterine leiomyoma tumor characteristics and disease risk

American Journal of Obstetrics and Gynecology

Volumn 199, Issue 6, 2008, Pages 648.e1-648.e9

  Renner, Stefan P ^a   Strick, Reiner ^a   Fasching, Peter A ^a   Oeser, Sonja ^a   Oppelt, Peter ^a   Mueller, Andreas ^a   Beckmann, Matthias W ^a   Strissel, Pamela L ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

fibroid; leiomyoma; progesterone receptor; single nucleotide polymorphisms

Indexed keywords

PROGESTERONE RECEPTOR; STEROID HORMONE; STEROID RECEPTOR;

ADULT; ARTICLE; BLOOD ANALYSIS; CANCER RISK; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; DNA DETERMINATION; ENDOMETRIOSIS; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HUMAN; LIFESTYLE; LIVE BIRTH; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SMOOTH MUSCLE FIBER; UTERUS MYOMA;

EID: 57149132678     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2008.06.015     Document Type: Article

References (68)

1. Cramer S.F., and Patel A. The frequency of uterine leiomyomas. Am J Clin Pathol 94 (1990) 435-438
2. Mueller A., Thiel F., Binder H., et al. Myome-Teil 1. Geburtsh Frauenheilk 64 (2004) R229-R244
3. Mueller A., Thiel F., Binder H., et al. Myome-Teil 2. Geburtsh Frauenheilk 64 (2004) R245-R260
4. Schwartz S.M. Epidemiology of uterine leiomyomata. Clin Obstet Gynecol 44 (2001) 316-326
5. Cramer S.F., Horiszny J.A., and Leppert P. Epidemiology of uterine leiomyomas. With an etiologic hypothesis. J Reprod Med 40 (1995) 595-600
6. Robboy S.J., Bentley R.C., Butnor K., and Anderson M.C. Pathology and pathophysiology of uterine smooth-muscle tumors. Environ Health Perspect 108 Suppl 5 (2000) 779-784
7. Payson M., Leppert P., and Segars J. Epidemiology of myomas. Obstet Gynecol Clin North Am 33 (2006) 1-11
8. Wilcox L.S., Koonin L.M., Pokras R., Strauss L.T., Xia Z., and Peterson H.B. Hysterectomy in the United States, 1988-1990. Obstet Gynecol 83 (1994) 549-555
9. Walker C.L., and Stewart E.A. Uterine fibroids: the elephant in the room. Science 308 (2005) 1589-1592
10. Przybora L.A. Leiomyosarcoma in situ of the uterus. Cancer 14 (1961) 483-492
11. Stewart E.A. Uterine fibroids. Lancet 357 (2001) 293-298
12. Sreekantaiah C., and Sandberg A.A. Clustering of aberrations to specific chromosome regions in benign neoplasms. Int J Cancer 48 (1991) 194-198
13. Flake G.P., Andersen J., and Dixon D. Etiology and pathogenesis of uterine leiomyomas: a review. Environ Health Perspect 111 (2003) 1037-1054
14. Meloni A.M., Surti U., Contento A.M., Davare J., and Sandberg A.A. Uterine leiomyomas: cytogenetic and histologic profile. Obstet Gynecol 80 (1992) 209-217
15. Pandis N., Heim S., Bardi G., Floderus U.M., Willen H., Mandahl N., et al. Chromosome analysis of 96 uterine leiomyomas. Cancer Genet Cytogenet 55 (1991) 11-18
16. Townsend D.E., Sparkes R.S., Baluda M.C., and McClelland G. Unicellular histogenesis of uterine leiomyomas as determined by electrophoresis by glucose-6-phosphate dehydrogenase. Am J Obstet Gynecol 107 (1970) 1168-1173
17. Pedeutour F., Quade B.J., Weremowicz S., Dal Cin P., Ali S., and Morton C.C. Localization and expression of the human estrogen receptor beta gene in uterine leiomyomata. Genes Chromosomes Cancer 23 (1998) 361-366
18. Buttram Jr. V.C. Uterine leiomyomata-aetiology, symptomatology and management. Prog Clin Biol Res 225 (1986) 275-296
19. Muram D., Gillieson M., and Walters J.H. Myomas of the uterus in pregnancy: ultrasonographic follow-up. Am J Obstet Gynecol 138 (1980) 16-19
20. Rosati P., Exacoustos C., and Mancuso S. Longitudinal evaluation of uterine myoma growth during pregnancy: a sonographic study. J Ultrasound Med 11 (1992) 511-515
21. Strobelt N., Ghidini A., Cavallone M., Pensabene I., Ceruti P., and Vergani P. Natural history of uterine leiomyomas in pregnancy. J Ultrasound Med 13 (1994) 399-401
22. Segaloff A., Weed J.C., et al. The progesterone therapy of human uterine leiomyomas. J Clin Endocrinol Metab 9 (1949) 1273-1291 illust
23. Tiltman A.J. The effect of progestins on the mitotic activity of uterine fibromyomas. Int J Gynecol Pathol 4 (1985) 89-96
24. Friedman A.J., Barbieri R.L., Doubilet P.M., Fine C., and Schiff I. A randomized, double-blind trial of a gonadotropin releasing-hormone agonist (leuprolide) with or without medroxyprogesterone acetate in the treatment of leiomyomata uteri. Fertil Steril 49 (1988) 404-409
25. Friedman A.J., Daly M., Juneau-Norcross M., Gleason R., Rein M.S., and LeBoff M. Long-term medical therapy for leiomyomata uteri: a prospective, randomized study of leuprolide acetate depot plus either oestrogen-progestin or progestin 'add-back' for 2 years. Hum Reprod 9 (1994) 1618-1625
26. Lamminen S., Rantala I., Helin H., Rorarius M., and Tuimala R. Proliferative activity of human uterine leiomyoma cells as measured by automatic image analysis. Gynecol Obstet Invest 34 (1992) 111-114
27. Murphy A.A., Kettel L.M., Morales A.J., Roberts V.J., and Yen S.S. Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J Clin Endocrinol Metab 76 (1993) 513-517
28. Strissel P.L., Swiatek J., Oppelt P., Renner S.P., Beckmann M.W., and Strick R. Transcriptional analysis of steroid hormone receptors in smooth muscle uterine leiomyoma tumors of postmenopausal patients. J Steroid Biochem Mol Biol 107 (2007) 42-47
29. Lydon J.P., DeMayo F.J., Funk C.R., Mani S.K., Hughes A.R., Montgomery Jr. C.A., et al. Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev 9 (1995) 2266-2278
30. Misrahi M., Venencie P.Y., Saugier-Veber P., Sar S., Dessen P., and Milgrom E. Structure of the human progesterone receptor gene. Biochim Biophys Acta 1216 (1993) 289-292
31. Rousseau-Merck M.F., Misrahi M., Loosfelt H., Milgrom E., and Berger R. Localization of the human progesterone receptor gene to chromosome 11q22-q23. Hum Genet 77 (1987) 280-282
32. Clarke C.L., and Sutherland R.L. Progestin regulation of cellular proliferation. Endocr Rev 11 (1990) 266-301
33. Graham J.D., and Clarke C.L. Physiological action of progesterone in target tissues. Endocr Rev 18 (1997) 502-519
34. Conneely O.M., Kettelberger D.M., Tsai M.J., Schrader W.T., and O'Malley B.W. The chicken progesterone receptor A and B isoforms are products of an alternate translation initiation event. J Biol Chem 264 (1989) 14062-14064
35. Conneely O.M., Maxwell B.L., Toft D.O., Schrader W.T., and O'Malley B.W. The A and B forms of the chicken progesterone receptor arise by alternate initiation of translation of a unique mRNA. Biochem Biophys Res Commun 149 (1987) 493-501
36. Kastner P., Krust A., Turcotte B., Stropp U., Tora L., Gronemeyer H., et al. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 9 (1990) 1603-1614
37. Sartorius C.A., Melville M.Y., Hovland A.R., Tung L., Takimoto G.S., and Horwitz K.B. A third transactivation function (AF3) of human progesterone receptors located in the unique N-terminal segment of the B-isoform. Mol Endocrinol 8 (1994) 1347-1360
38. Wen D.X., Xu Y.F., Mais D.E., Goldman M.E., and McDonnell D.P. The A and B isoforms of the human progesterone receptor operate through distinct signaling pathways within target cells. Mol Cell Biol 14 (1994) 8356-8364
39. Brandon D.D., Bethea C.L., Strawn E.Y., Novy M.J., Burry K.A., Harrington M.S., et al. Progesterone receptor messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas. Am J Obstet Gynecol 169 (1993) 78-85
40. Viville B., Charnock-Jones D.S., Sharkey A.M., Wetzka B., and Smith S.K. Distribution of the A and B forms of the progesterone receptor messenger ribonucleic acid and protein in uterine leiomyomata and adjacent myometrium. Hum Reprod 12 (1997) 815-822
41. Berchuck A., Schildkraut J.M., Wenham R.M., Calingaert B., Ali S., Henriott A., et al. Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers. Cancer Epidemiol Biomarkers Prev 13 (2004) 2141-2147
42. Cramer D.W., Hornstein M.D., McShane P., Powers R.D., Lescault P.J., Vitonis A.F., et al. Human progesterone receptor polymorphisms and implantation failure during in vitro fertilization. Am J Obstet Gynecol 189 (2003) 1085-1092
43. De Vivo I., Huggins G.S., Hankinson S.E., Lescault P.J., Boezen M., Colditz G.A., et al. A functional polymorphism in the promoter of the progesterone receptor gene associated with endometrial cancer risk. Proc Natl Acad Sci U S A 99 (2002) 12263-12268
44. Dossus L., Canzian F., Kaaks R., Boumertit A., and Weiderpass E. No association between progesterone receptor gene +331G/A polymorphism and endometrial cancer. Cancer Epidemiol Biomarkers Prev 15 (2006) 1415-1416
45. Feigelson H.S., Rodriguez C., Jacobs E.J., Diver W.R., Thun M.J., and Calle E.E. No association between the progesterone receptor gene +331G/A polymorphism and breast cancer. Cancer Epidemiol Biomarkers Prev 13 (2004) 1084-1085
46. Risch H.A., Bale A.E., Beck P.A., and Zheng W. PGR +331 A/G and increased risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 15 (2006) 1738-1741
47. Romano A., Lindsey P.J., Fischer D.C., Delvoux B., Paulussen A.D., Jansenn R.G., et al. Two functionally relevant polymorphisms in the human progesterone receptor gene (+331 G/A and progins) and the predisposition for breast and/or ovarian cancer. Gynecol Oncol 101 (2006) 287-295
48. van Kaam K.J., Romano A., Schouten J.P., Dunselman G.A., and Groothuis P.G. Progesterone receptor polymorphism +331G/A is associated with a decreased risk of deep infiltrating endometriosis. Hum Reprod 22 (2007) 129-135
49. De Vivo I., Hankinson S.E., Colditz G.A., and Hunter D.J. The progesterone receptor Val660->Leu polymorphism and breast cancer risk. Breast Cancer Res 6 (2004) R636-R639
50. Spurdle A.B., Hopper J.L., Chen X., McCredie M.R., Giles G.G., Venter D.J., et al. The progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of breast cancer in Australian women. Cancer Epidemiol Biomarkers Prev 11 (2002) 439-443
51. Spurdle A.B., Webb P.M., Purdie D.M., Chen X., Green A., and Chenevix-Trench G. No significant association between progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of ovarian cancer. Carcinogenesis 22 (2001) 717-721
52. Terry K.L., De Vivo I., Titus-Ernstoff L., Sluss P.M., and Cramer D.W. Genetic variation in the progesterone receptor gene and ovarian cancer risk. Am J Epidemiol 161 (2005) 442-451
53. Romano A., Delvoux B., Fischer D.C., and Groothuis P. The PROGINS polymorphism of the human progesterone receptor diminishes the response to progesterone. J Mol Endocrinol 38 (2007) 331-350
54. Govindan S., Ahmad S.N., Vedicherla B., Kodati V., Jahan P., Rao K.P., et al. Association of progesterone receptor gene polymorphism (PROGINS) with endometriosis, uterine fibroids and breast cancer. Cancer Biomark 3 (2007) 73-78
55. Junqueira M.G., da Silva I.D., Nogueira-de-Souza N.C., Carvalho C.V., Leite D.B., Gomes M.T., et al. Progesterone receptor (PROGINS) polymorphism and the risk of endometrial cancer development. Int J Gynecol Cancer 17 (2007) 229-232
56. Massart F., Becherini L., Marini F., Noci I., Piciocchi L., Del Monte F., et al. Analysis of estrogen receptor (ERalpha and ERbeta) and progesterone receptor (PR) polymorphisms in uterine leiomyomas. Med Sci Monit 9 (2003) BR25-BR30
57. Hsieh Y.Y., Chan I.P., Wang H.I., Chang C.C., Huang C.W., and Lin C.S. PROGINS Alu sequence insertion is associated with hyperprolactinaemia but not leiomyoma susceptibility. Clin Endocrinol (Oxf) 62 (2005) 492-497
58. Gomes M.T., Castro Rde A., Villanova F.E., da Silva I.D., Baracat E.C., de Lima G.R., et al. The progesterone receptor gene polymorphism, PROGINS, may be a factor related to the development of uterine fibroids. Fertil Steril 87 (2007) 1116-1121
59. Oppelt P., Strissel P.L., Kellermann A., Seeber S., Humeny A., Beckmann M.W., et al. DNA sequence variations of the entire anti-Mullerian hormone (AMH) gene promoter and AMH protein expression in patients with the Mayer-Rokitanski-Kuster-Hauser syndrome. Hum Reprod 20 (2005) 149-157
60. Renner S.P., Strick R., Oppelt P., Fasching P.A., Engel S., Baumann R., et al. Evaluation of clinical parameters and estrogen receptor alpha gene polymorphisms for patients with endometriosis. Reproduction 131 (2006) 153-161
61. Giangrande P.H., Pollio G., and McDonnell D.P. Mapping and characterization of the functional domains responsible for the differential activity of the A and B isoforms of the human progesterone receptor. J Biol Chem 272 (1997) 32889-32900
62. Matthews J., and Gustafsson J.A. Estrogen signaling: a subtle balance between ER alpha and ER beta. Mol Interv 3 (2003) 281-292
63. Schweikert A., Rau T., Berkholz A., Allera A., Daufeldt S., and Wildt L. Association of progesterone receptor polymorphism with recurrent abortions. Eur J Obstet Gynecol Reprod Biol 113 (2004) 67-72
64. Walker C.L., Hunter D., and Everitt J.I. Uterine leiomyoma in the Eker rat: a unique model for important diseases of women. Genes Chromosomes Cancer 38 (2003) 349-356
65. Cook J.D., Davis B.J., Goewey J.A., Berry T.D., and Walker C.L. Identification of a sensitive period for developmental programming that increases risk for uterine leiomyoma in Eker rats. Reprod Sci 14 (2007) 121-136
66. Wei J.J., Chiriboga L., and Mittal K. Expression profile of the tumorigenic factors associated with tumor size and sex steroid hormone status in uterine leiomyomata. Fertil Steril 84 (2005) 474-484
67. Rein M.S. Advances in uterine leiomyoma research: the progesterone hypothesis. Environ Health Perspect 108 Suppl 5 (2000) 791-793
68. Pijnenborg J.M., Romano A., Dam de Veen G.C., et al. Aberrations in the progesterone receptor gene and the risk of recurrent endometrial carcinoma. J Pathol 205 (2005) 597-605